Race Oncology Limited (ASX: RAC) has taken another important step forward in its mission of “protecting patients while optimising their cancer treatment.” The company has now dosed the first patient in its Phase 1 trial of RC220, the reformulated version of bisantrene designed to deliver both anti-cancer efficacy and cardioprotection.